The vaccine-maker saw better-than-expected profits for the last three months of 2021, with revenue reaching $7.21 billion, as the company's Covid-19 shot continued to power its growth.
The vaccine-maker saw better-than-expected profits for the last three months of 2021, with revenue reaching $7.21 billion, as the company's Covid-19 shot continued to power its growth.
Share this Article
Recommended